毅嘉管理顧問股份有限公司
Update：2025/12/03
Industries
Main Industry
Professional Services
Main Product/Service
Definition of prodrug: Use chemical engineering methods that connect an existing drug with a promoiety to form a prodrug.
The prodrug technology we developed can resolve developmental barriers of certain drug candidates; such as solubility, chemical stability, side effects and toxicities.
Chemically generate new drug candidate from existing drugs with known healing effect. After the prodrug is absorbed by the human body, through the enzymatic actions or other actions, the original parent drug is released its anti-cancer effect is realized.
Prodrugs are new chemical entities that have been patented in the United States, Europe, China, Japan and Taiwan.
Advantages of prodrugs
Increase the duration of the drug efficacy.
Reduce adverse drug reactions and side effects.
Improves drug oral absorption.
Promote targeted release of drug.
Increase patient drug-intake compliance.
Improve drug bioavailability(BA)
The prodrug technology we developed can resolve developmental barriers of certain drug candidates; such as solubility, chemical stability, side effects and toxicities.
Chemically generate new drug candidate from existing drugs with known healing effect. After the prodrug is absorbed by the human body, through the enzymatic actions or other actions, the original parent drug is released its anti-cancer effect is realized.
Prodrugs are new chemical entities that have been patented in the United States, Europe, China, Japan and Taiwan.
Advantages of prodrugs
Increase the duration of the drug efficacy.
Reduce adverse drug reactions and side effects.
Improves drug oral absorption.
Promote targeted release of drug.
Increase patient drug-intake compliance.
Improve drug bioavailability(BA)
Founded Year
2019
Unified Business No.
54996030
Status
Closed
Number of Employees
0
Total Paid-in
Capital
1,000,000 (NT$)
Location of Company
Taiwan
, Tainan City
Website
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
BoYen Therapeutics Inc. was established in June 2010. In its early years BoYen Therapeutics focused on new drug research and discovery, through our own proprietary prodrug technology platform, we perform chemosynthesis modification and create new patentable drug candidates. Our goal is to provide innovative medical options for patients, and maximize shareholder value at the same time.
After 10 years of painstaking work, we successfully created a prodrug technology platform which is capable of creating high-commercial-value patentable new drug candidates. Currently, BoYen Therapeutics also has a product pipeline with abundance of commercial value. BY-101 is an USFDA designated orphan drug with 7-year period marketing exclusivity. BY-101 is intended for the treatment of acute myeloid leukemia (AML). BY-102, BY-103 and BYT-3156 are patented drug candidates for the treatment of multiple sclerosis, leukemia, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and other indications.
The year 2020 is a year of transition for BoYen Therapeutics. The company decided it is time to commercialize its drug candidates and place most of its efforts on clinical development while maintaining a certain level of drug discovery to gradually increase its pipeline. BY-101 will enter Phase 2/3 clinical trials through USFDA 505(b)2 pathway in 2021. The company is also working on pre-clinical studies for BY-102, a drug candidate with an immense trillion-US dollar business opportunity.
After 10 years of painstaking work, we successfully created a prodrug technology platform which is capable of creating high-commercial-value patentable new drug candidates. Currently, BoYen Therapeutics also has a product pipeline with abundance of commercial value. BY-101 is an USFDA designated orphan drug with 7-year period marketing exclusivity. BY-101 is intended for the treatment of acute myeloid leukemia (AML). BY-102, BY-103 and BYT-3156 are patented drug candidates for the treatment of multiple sclerosis, leukemia, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and other indications.
The year 2020 is a year of transition for BoYen Therapeutics. The company decided it is time to commercialize its drug candidates and place most of its efforts on clinical development while maintaining a certain level of drug discovery to gradually increase its pipeline. BY-101 will enter Phase 2/3 clinical trials through USFDA 505(b)2 pathway in 2021. The company is also working on pre-clinical studies for BY-102, a drug candidate with an immense trillion-US dollar business opportunity.
